Industry8 min read
Ozempic Pill Launches in US: New Dose Strengths
Novo Nordisk's reformulated Ozempic tablets (1.5, 4, 9 mg) hit US pharmacies May 4. What changed, the new prices, and where compounded still wins.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Trials6 min read
Survodutide Phase 3: 16.6% Weight Loss in SYNCHRONIZE-1
Boehringer's GLP-1/glucagon dual agonist hit 16.6% weight loss at 76 weeks — comparable to semaglutide, short of tirzepatide. What it means for buyers.
Industry7 min read
Medicaid GLP-1 Coverage Starts May 1: BALANCE Model Live
CMS launched BALANCE Medicaid GLP-1 coverage May 1 — but Part D was just delayed. What it means for branded vs compounded buyers right now.
Regulatory5 min read
Ex-FDA Officials Push Back on RFK Peptide Reversal
Three former FDA officials say RFK Jr. mischaracterized their 2023 peptide-safety work. What the pushback means for buyers before the July 23 PCAC vote.
Regulatory8 min read
FDA Targets 503B GLP-1 Compounding: What Now
FDA proposed April 30 to bar 503B compounding of semaglutide, tirzepatide, and liraglutide. The comment window closed July 30. What survives the rule.
Trials6 min read
Eloralintide: Lilly Amylin Drug Hits 20% Weight Loss
Lilly's eloralintide hit 20% weight loss at 48 weeks in Phase 2 — without GLP-1. Here's what the amylin-only data means for obesity drugs.
Trials9 min read
Pfizer's Monthly GLP-1 Shot PF-3944: Phase 2b Results
Pfizer's once-monthly GLP-1 shot PF-3944 hit 12.3% placebo-adjusted weight loss in phase 2b. 10 phase 3 trials launching. Here is what it means.
Pricing7 min read
Oral Semaglutide Pill Price Hike: $199-$299 Now
GoodRx ended $149 introductory pricing on April 15. The 4 mg pill jumps to $199, the 9 mg and 25 mg pills to $299. Here is what to do about it.
Trials6 min read
Semaglutide Cuts Heart Risk 29% More Than Tirzepatide
New STEER study: semaglutide cut major cardiac events 29% more than tirzepatide in obesity patients without diabetes. What it means for stack choice.
Vendors9 min read
Dynamic Peptide Review: 10% Off + COA Check
25+ peptides, broad catalog including MOTS-c, DSIP, and Epitalon. We checked the testing, pricing, and code against every vendor we track.
Vendors3 min read
BioLongevity Labs Review
BioLongevity Labs is a US research-peptide vendor focused on specialty and longevity compounds. How they operate and the vendors we track side by side.
Vendors4 min read
Best Peptide Vendors 2026: COA-Tested Sources Ranked
5 vendors compared on third-party COA, price, and shipping reliability. Scorecard with $/mg comparison and which ones don't pass our test.
Trials7 min read
Semaglutide Reverses Knee Cartilage: New Study
May 2026 research: semaglutide reverses knee cartilage damage independent of weight loss. MRI showed 17% thicker cartilage. What it means.
Trials6 min read
Retatrutide Tingling: 20.9% Hit by Dysesthesia
TRIUMPH-4 Phase 3 found 1 in 5 patients on retatrutide 12mg develop dysesthesia. What it feels like, why it happens, and how to manage it without quitting.
Industry5 min read
The Peptide Media Panic: What They Got Wrong
The New Yorker, NBC, and STAT ran peptide scare stories in April 2026. Here is what they nailed, what they missed, and how to actually stay safe.
Regulatory4 min read
Orforglipron Approved: First Oral GLP-1 Pill
FDA approved orforglipron April 1 at $149/mo -- but compounded semaglutide still beats it on weight loss. Full cost and efficacy comparison inside.
Industry8 min read
GLP-1 Not Needed for Weight Loss? GIP/Glucagon
DiMarchi, who pioneered GLP-1 obesity drugs, now says GIP/glucagon alone may match GLP-1 — without nausea. What it means for retatrutide buyers.
Industry4 min read
GLP-1 Genetic Resistance: What to Do If You're a Non-Responder
10% of people carry gene variants that reduce GLP-1 drug response. How to tell if you're one, what the research says, and which alternatives actually work.